Skip to content

Inspection prep notes · Quality system

Complaint handling

Also called: product complaint, customer complaint

FDA looks less at whether complaints were received than at whether each one was investigated for cause and scope and the work was recorded. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1Complaint investigations were not thorough

You failed to adequately investigate customer complaints for the large volume parenteral (LVP) bag drug products you manufacture. Your investigations were not thorough and did not appropriately evaluate the risk to product quality.

FDA Warning Letter · Fresenius Medical Care AG & Co. KGaA · 2026-09-01

Investigations do not include a thorough evaluation of all possible factors in the manufacturing process that could have contributed to the complaint or defect.

FDA 483 · Jiangsu Hansoh Pharmaceutical Group Co Ltd. · 2026-10-22 · View document

2The investigation was not extended to other batches or lots

You indicated that the probable root cause of (b)(4) pieces and missing (b)(4) was equipment vibrations during manufacturing, but you did not extend the investigation to other batches processed on the same equipment.

FDA Warning Letter · CareFusion 213, LLC · 2026-05-05 · View document

Specifically, your QU failed to extend product quality complaint investigations to other lots of APIs potentially associated with the root cause, failure, or deviation.

FDA Warning Letter · Darmerica, LLC · 2025-12-23 · View document

3The complaint procedure was inadequate

Your complaint procedure is inadequate because not all quality related issues are investigated. You only investigate complaints related to adverse event, foreign matter, and incorrect product.

FDA Warning Letter · Colgate-Palmolive/Tom's of Maine, Inc. · 2024-11-19 · View document

For example, your procedure for customer complaints and inquiries is inadequate. Your approach to determining severity and adverse events resulted in delayed and incomplete investigations.

FDA Warning Letter · K.C. Pharmaceuticals, Inc. · 2026-08-18 · View document

4Complaint records did not document the investigation

My review of the complaints found that your firm kept a list of the complaints that lacked critical information including product name, lot number, root cause analysis, conclusions, and assessment of impact to other lots.

FDA 483 · Gascó Industrial Corporation · 2026-07-28 · View document

The investigation report MC/006/25/006 does not document any review of the batch production records, packing records, environmental monitoring data, or visual inspection records for the batch related to the particle complaint.

FDA 483 · Maiva Pharma Private Limited · 2026-03-06 · View document

5There was no documented evaluation of complaint trends

Although you state complaint investigations were not required because there was no trend identified, you did not provide a documented evaluation determining the lack of trend for the quality issue specific to each complaint.

FDA Warning Letter · Colgate-Palmolive/Tom's of Maine, Inc. · 2024-11-19 · View document

Further, your records of trend analysis for complaint data in December 2023, January 2024, and February 2024 do not list an evaluation covering Alert Limit deviations which were identified during these reviews.

FDA 483 · CSL Behring GmbH · 2026-10-20

Questions to check against your procedures

  1. Do complaint investigations evaluate all manufacturing factors that could have contributed to the complaint, and the risk to product quality?
  2. When the cause is attributed to equipment or process, is the investigation extended to other batches run on the same equipment and to other lots that may be associated?
  3. Does the complaint procedure avoid limiting investigations to only some types of complaints?
  4. Does the way complaint severity is determined avoid delayed or incomplete investigations?
  5. Do complaint records include product name, lot number, root cause analysis, conclusions and impact on other lots, and does the investigation report document the review of batch records?
  6. Are the basis for concluding there is no trend, and the evaluation of alert limit excursions, documented?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-16.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.